UNSPSC 51203301: Lenalidomide

This classification denotes a biological response modifier with the molecular formula C13H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) F0P408N6V4, chemically known as 2,6-piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2h-isoindol-2-yl)- but more generally known as lenalidomide, which bears US NIH Compound Identifier 216326. European Medicines Agency schedules Lenalidomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25389.

UNSPSC 51203301 Lenalidomide is a Commodity code for a specific prescription pharmaceutical product, but the recent state and local solicitations tagged under this code do not reflect lenalidomide procurement. Instead, the opportunities show state and local health agencies purchasing other pharmaceuticals and medical supplies through piggyback contracts and competitive bids. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets under a 12-month initial term with renewal options, valued at $2,999,999.11 over the contract life. Seminole County, Florida released a competitive bid in June 2026 for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the county's Community Health Building, under an IFB with an initial two-year term and one-year renewal option. The issuing bodies are state health departments and county health agencies using cooperative purchasing vehicles and traditional competitive bidding to source pharmaceutical and medical products.

The code shows recent activity in Florida and Illinois. The mismatch between the code's nominal scope (lenalidomide, a specific oncology pharmaceutical) and the actual recent opportunities (antibiotics, opioid-reversal agents, and drug deactivation systems) suggests either inconsistent code tagging by the issuing agencies or that the code is used as a catch-all for pharmaceutical procurement. Business development professionals should verify with issuing bodies whether lenalidomide-specific demand exists separate from these broader pharmaceutical solicitations, as the recent record does not demonstrate active state and local procurement of lenalidomide itself.